125 related articles for article (PubMed ID: 6469517)
1. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice.
Roberts JD; Hacker MP; Newman RA; McCormack JJ; Krakoff IH
Invest New Drugs; 1984; 2(2):215-20. PubMed ID: 6469517
[TBL] [Abstract][Full Text] [Related]
2. Experimental toxicology of ASTA Z 7557 (INN mafosfamide).
Pohl J; Hilgard P; Jahn W; Zechel HJ
Invest New Drugs; 1984; 2(2):201-6. PubMed ID: 6469515
[TBL] [Abstract][Full Text] [Related]
3. Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia.
Zaharko DS; Covey JM; Hörpel G
Invest New Drugs; 1984; 2(2):149-54. PubMed ID: 6469508
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of therapeutic activity, myelotoxicity and DNA damage in the bone marrow of mice after cyclophosphamide and ASTA Z 7557 (INN mafosfamide).
Berger MR; Bedford P; Zeller WJ; Kaufmann M
Invest New Drugs; 1984; 2(2):181-6. PubMed ID: 6469513
[TBL] [Abstract][Full Text] [Related]
5. Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide.
Skórski T; Kawalec M
Exp Hematol; 1988 Oct; 16(9):782-4. PubMed ID: 3049130
[TBL] [Abstract][Full Text] [Related]
6. Regional fibrosis after intraperitoneal administration of mafosfamide.
Roberts JD; Newman RA; Kimberly PJ; Hacker MP
Invest New Drugs; 1986; 4(1):61-5. PubMed ID: 2939038
[TBL] [Abstract][Full Text] [Related]
7. Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide.
Wagner T; Zink M; Schwieder G
J Cancer Res Clin Oncol; 1987; 113(2):160-5. PubMed ID: 3104347
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide).
Alberts DS; Einspahr JG; Struck R; Bignami G; Young L; Surwit EA; Salmon SE
Invest New Drugs; 1984; 2(2):141-8. PubMed ID: 6469507
[TBL] [Abstract][Full Text] [Related]
9. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.
Nowrousian MR; Schmidt CG
Invest New Drugs; 1984; 2(2):207-13. PubMed ID: 6469516
[TBL] [Abstract][Full Text] [Related]
11. Antitumoral activity of the oxazaphosphorine derivative, mafosfamide-cyclohexylamine salt (ASTA 7557) on a murine ovarian reticular cell sarcoma and its subline resistant to cyclophosphamide.
Colombo T; Paolini A; Finazzi M; Scanziani E; Mandelli G; Donelli MG
Tumori; 1986 Dec; 72(6):637-42. PubMed ID: 3544404
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of toxicity and therapeutic efficacy of a stabilized cytostatic metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide).
Klein HO; Wickramanayake PD; Christian E; Coerper C
Invest New Drugs; 1984; 2(2):191-9. PubMed ID: 6469514
[TBL] [Abstract][Full Text] [Related]
13. Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654).
Skórski T; Kawalec M
Bone Marrow Transplant; 1987 Dec; 2(4):435-40. PubMed ID: 3332191
[TBL] [Abstract][Full Text] [Related]
14. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine.
Bruntsch U; Groos G; Hiller TA; Wandt H; Tigges FJ; Gallmeier WM
Invest New Drugs; 1985; 3(3):293-6. PubMed ID: 4066222
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated macrophages stimulate the proliferation of murine tumor cells surviving treatment with the oncolytic cyclophosphamide analogue Asta Z-7557: in vivo implications.
Evans R; Duffy T; Cullen RT
Int J Cancer; 1984 Dec; 34(6):883-90. PubMed ID: 6511127
[TBL] [Abstract][Full Text] [Related]
16. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
Kawalec M; Skórski T; Kawiak J
Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382
[TBL] [Abstract][Full Text] [Related]
17. Macromolecular DNA-damage in murine and human leukemic and lymphoid cells after in vitro exposure to ASTA Z 7557 (INN mafosfamide).
Osieka R; Pannenbäcker R; Schmidt CG
Invest New Drugs; 1984; 2(2):161-8. PubMed ID: 6469510
[TBL] [Abstract][Full Text] [Related]
18. Effect of disulfiram (tetraethylthiuram disulfide) amd diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice.
Hacker MP; Ershler WB; Newman RA; Gamelli RL
Cancer Res; 1982 Nov; 42(11):4490-4. PubMed ID: 6290038
[TBL] [Abstract][Full Text] [Related]
19. Murine strain differences in metabolism and bladder toxicity of cyclophosphamide.
Fraiser L; Kehrer JP
Toxicology; 1992 Nov; 75(3):257-72. PubMed ID: 1455433
[TBL] [Abstract][Full Text] [Related]
20. Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors.
Atassi G; Hilgard P; Pohl J
Invest New Drugs; 1984; 2(2):169-73. PubMed ID: 6469511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
